4.7 Review

Quantitative Imaging Biomarkers in Age-Related Macular Degeneration and Diabetic Eye Disease: A Step Closer to Precision Medicine

Journal

JOURNAL OF PERSONALIZED MEDICINE
Volume 11, Issue 11, Pages -

Publisher

MDPI
DOI: 10.3390/jpm11111161

Keywords

retinal imaging; quantitative biomarkers; diabetic retinopathy; diabetic macular edema; age-related macular degeneration; precision medicine; anti-VEGF therapy

Funding

  1. Regeneron
  2. Allergan
  3. Gilead
  4. Astrazeneca
  5. Bristol Myers-Squibb
  6. Philips
  7. Roche
  8. Aerpio
  9. NIH/NEI [K23-EY022947-01A1]

Ask authors/readers for more resources

The management of retinal diseases relies heavily on digital imaging data, including OCT and FA. Advances in computational technology, such as deep learning and radiomics, open new doors for developing personalized disease characterization, enhancing opportunities in precision medicine.
The management of retinal diseases relies heavily on digital imaging data, including optical coherence tomography (OCT) and fluorescein angiography (FA). Targeted feature extraction and the objective quantification of features provide important opportunities in biomarker discovery, disease burden assessment, and predicting treatment response. Additional important advantages include increased objectivity in interpretation, longitudinal tracking, and ability to incorporate computational models to create automated diagnostic and clinical decision support systems. Advances in computational technology, including deep learning and radiomics, open new doors for developing an imaging phenotype that may provide in-depth personalized disease characterization and enhance opportunities in precision medicine. In this review, we summarize current quantitative and radiomic imaging biomarkers described in the literature for age-related macular degeneration and diabetic eye disease using imaging modalities such as OCT, FA, and OCT angiography (OCTA). Various approaches used to identify and extract these biomarkers that utilize artificial intelligence and deep learning are also summarized in this review. These quantifiable biomarkers and automated approaches have unleashed new frontiers of personalized medicine where treatments are tailored, based on patient-specific longitudinally trackable biomarkers, and response monitoring can be achieved with a high degree of accuracy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available